Blanche Saunders Dermatology Laboratory, Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, 2015 SW 16th Avenue, Gainesville, FL, 32610, USA.
Vet Dermatol. 2020 Aug;31(4):284-e69. doi: 10.1111/vde.12849. Epub 2020 Apr 17.
No study has directly compared the various treatment options for canine atopic dermatitis and their effects on skin barrier.
HYPOTHESIS/OBJECTIVES: To compare prednisone, oclacitinib, ciclosporin and lokivetmab treatment of atopic dermatitis.
Nineteen atopic beagle dogs.
Controlled, blinded study. Dogs were challenged with allergen twice weekly and randomized to oclacitinib, ciclosporin, lokivetmab, prednisone or no treatment for four weeks. Dermatitis and pruritus were assessed at baseline and after each challenge. Transepidermal water loss (TEWL) and hydration were measured at baseline, Day (D)14 and D28 (pinnae, axilla, groin). Area under the curve (AUC) was calculated for Canine Atopic Dermatitis Extent and Severity Index, 3rd iteration (CADESI-03), pruritus, TEWL and hydration. For CADESI, the AUC of the first two weeks was compared to that of the last two weeks.
For CADESI, restricted maximum-likelihood ANOVA showed effect of time (P = 0034) and group x time interaction (P = 0.0169). In the first two weeks, prednisone and oclacitinib were significantly lower than controls (P = 0.019 and P = 0.015, respectively). Lokivetmab prevented flares. Due to variability, no significance differences in pruritus were observed among groups. The TEWL increased with time in controls (P = 0.0237) and ciclosporin (P = 0.04, axilla, D28 versus D0) but not in the oclacitinib and lokivetmab groups. CADESI-03 correlated with TEWL (P = 0.0043) and pruritus (P = 0.0283). Hydration did not correlate with any parameters. Hydration decreased in controls and prednisone group (axilla, D14 versus D0, P = 0.004 and P = 0.027, respectively). AUC for hydration, over time, was higher for lokivetmab and oclacitinib than controls (P = 0.014 and P = 0.04, respectively).
Lokivetmab prevented flares when given before challenge. Oclacitinib and lokivetmab have some positive effects on skin barrier parameters.
尚无研究直接比较过犬特应性皮炎的各种治疗选择及其对皮肤屏障的影响。
假设/目的：比较泼尼松、奥克利替尼、环孢素和洛维莫司他治疗特应性皮炎的效果。
19 只特应性比格犬。
对照、盲法研究。犬每周接受两次过敏原挑战，并随机分为奥克利替尼、环孢素、洛维莫司他、泼尼松或不治疗 4 周。在基线和每次挑战后评估皮炎和瘙痒。在基线、第 14 天（D14）和第 28 天（耳尖、腋窝、腹股沟）测量经皮水分丢失（TEWL）和皮肤水分。计算犬特应性皮炎严重度和严重程度指数（CADESI-03）、瘙痒、TEWL 和皮肤水分的曲线下面积（AUC）。对于 CADESI，比较前两周和后两周的 AUC。
对于 CADESI，受限最大似然方差分析显示时间的影响（P=0.0034）和组与时间的交互作用（P=0.0169）。在前两周，泼尼松和奥克利替尼显著低于对照组（P=0.019 和 P=0.015）。洛维莫司他可预防发作。由于变异性，各组之间瘙痒无显著差异。对照组和环孢素组 TEWL 随时间增加（P=0.0237 和 P=0.04，腋窝，D28 与 D0），而奥克利替尼和洛维莫司他组则没有。CADESI-03 与 TEWL（P=0.0043）和瘙痒（P=0.0283）相关。皮肤水分与任何参数均无关。对照组和泼尼松组皮肤水分减少（腋窝，D14 与 D0，P=0.004 和 P=0.027）。与对照组相比，洛维莫司他和奥克利替尼的皮肤水分 AUC 随时间升高（P=0.014 和 P=0.04）。
洛维莫司他在挑战前给予时可预防发作。奥克利替尼和洛维莫司他对皮肤屏障参数有一些积极影响。
